financetom
Business
financetom
/
Business
/
Xperi, Imax, Sony Pictures Expand Collaboration
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Xperi, Imax, Sony Pictures Expand Collaboration
Sep 4, 2025 2:56 AM

05:32 AM EDT, 09/04/2025 (MT Newswires) -- Xperi ( XPER ) unit DTS and Imax ( IMAX ) said Thursday that Sony (SONY) Pictures Entertainment plans to expand its catalog of Imax ( IMAX )-enhanced content featuring DTS:X immersive sound.

The expansion will add hundreds of Sony Pictures titles to catalog of films available in the format.

Content from the catalog is expected to be first available via ad-supported video on demand on certain Hisense and Toshiba television models in the UK and Germany beginning early next year, the companies said.

Xperi ( XPER ) shares were up 1.4% in recent premarket activity, while Sony ( SONY ) rose 2.3%. Imax ( IMAX ) was down 0.2%.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
ARCpoint Agrees to Sell 68% Ownership Stake in Non-Core Assets
ARCpoint Agrees to Sell 68% Ownership Stake in Non-Core Assets
Dec 30, 2024
05:20 PM EST, 12/30/2024 (MT Newswires) -- ARCpoint ( ARCPF ) after trade Monday entered into an agreement for the sale of its 68% share ownership interest in Achieve Behavioral Health Greenville LLC, a non-core assset, for total consideration of US$480,000. The buyer of ARCpoint's ( ARCPF ) interest in Achieve will deduct US$120,000 in recognition of net amounts owing...
Verastem's Ovarian Cancer Drug Application Accepted by FDA, Gets Priority Review
Verastem's Ovarian Cancer Drug Application Accepted by FDA, Gets Priority Review
Dec 30, 2024
05:17 PM EST, 12/30/2024 (MT Newswires) -- Verastem ( VSTM ) said Monday that the US Food and Drug Administration accepted for review the new drug application for avutometinib in combination with defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer that received at least one systemic treatment and have KRAS mutation. The FDA granted priority review...
Siemens reviewing Healthineers majority stake, CFO tells Handelsblatt
Siemens reviewing Healthineers majority stake, CFO tells Handelsblatt
Dec 30, 2024
MUNICH (Reuters) - Siemens AG is reviewing its majority stake in medical technology subsidiary Siemens Healthineers,, the German technology group's Chief Financial Officer Ralf Thomas told the Handelsblatt newspaper. The synergies with the manufacturer of MRI machines and laboratory systems are not great enough to justify a capital commitment of 45 billion euros ($46.91 billion), Thomas told Handelsblatt, referring to...
Gitlab Insider Sold Shares Worth $32,714,896, According to a Recent SEC Filing
Gitlab Insider Sold Shares Worth $32,714,896, According to a Recent SEC Filing
Dec 30, 2024
05:17 PM EST, 12/30/2024 (MT Newswires) -- Matthew Jacobson, Director, on December 26, 2024, sold 547,779 shares in Gitlab ( GTLB ) for $32,714,896. Following the Form 4 filing with the SEC, Jacobson has control over a total of 4,753,830 shares of the company, with 551,618 shares held directly and 4,202,212 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1653482/000095017024141192/xslF345X05/ownership.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved